A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer reports their earnings Tuesday, Jan. 31, 2023. (AP Photo/Mark Lennihan, File)COVID-19 vaccine booster shots and treatments for the virus helped push Pfizer to a better-than-expected final quarter of 2022.
The drugmaker also debuted on Tuesday a 2023 forecast that starts off well below Wall Street forecasts.
In the recently completed fourth quarter, Pfizer booked nearly half of its $24.29 billion in revenue from its top-selling COVID-19 vaccine Comirnaty and another $1.8 billion from the treatment Paxlovid.
Overall, the drugmaker posted adjusted earnings of $1.14 per share.
Analysts forecast fourth-quarter earnings of $1.05 per share on $24.38 billion in revenue, according to FactSet.
For the new year, Pfizer expects adjusted earnings to range between $3.25 and $3.45 per share.
Analysts expect earnings of $4.34 per share for 2023, according to FactSet.
Shares of New York-based Pfizer Inc. started to tumble in early-morning trading.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
